So why in your estimation can they not get this technology up and profitable with all the recent FDA approvals? Is the technology viable or is the CEO just beating a dead horse to continue a salary? Is there buyout value in this product? An honest response of someone familiar with this industry would be appreciated and just not for the sake of bashing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.